Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunogenicity of durvalumab: Analysis of pooled pan-tumor data
    Meeting Abstract

    El-Khoueiry, A.; Zhou, D.; Ozguroglu, M.; Johnson, M.; Abou-Alfa, G.; Makowsky, M.; Krug, L.; Gupta, A.; Chen, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Amadeus trial: Tumor agnostic pre- and ontreatment biomarkers of response to nivolumab plus ipilimumab correlate with ontreatment tumoral T cell infiltration
    Meeting Abstract

    Alayli, F.; Okrah, K.; Tsimberidou, A.; Drakaki, A.; Khalil, D.; Khan, S.; Hodi, S.; Oh, D.; Amouzgar, M.; Guatam, S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214
    Meeting Abstract

    Gupta, S.; Han, C.; Dwivedi, B.; Li, J.; Karsdal, M.; Motzer, R.; Willumsen, N.; McDermott, D.; Choueiri, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 porter platform trial in metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Shotts, K.; Howes, T.; Yu, J.; Densmore, J.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Cabanski, C.; Eisenbeisz, E.; Ivison, G.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial
    Meeting Abstract

    Saatcioglu, H. D.; Valle, J.; Macarulla, T.; Javle, M.; Oh, D. Y.; Goyal, L.; Conway, J.; Iyer, J.; Najdawi, F.; Shah, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Clinical and pharmacodynamic biomarker results from porter, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Galsky, M.; Autio, K.; Wentzel, K.; Graff, J.; Friedlander, T.; Densmore, J.; Cabanski, C.; Shotts, K.; Howes, T.; Yu, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade
    Meeting Abstract

    Nabet, B.; Hamidi, H.; Banchereau, R.; Morris, S.; Adler, L.; Srivastava, M.; Patil, N.; Gay, C.; Minna, J.; Heymach, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
    Meeting Abstract

    Bortone, D.; Monette, A.; Tschernia, N.; Cogdill, A.; Najjar, Y.; Sweis, R. F.; Valpione, S.; Wennerberg, E.; Bommareddy, P.; Haymaker, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): A matched cohort study from the International Catch-It Consortium
    Meeting Abstract

    El Zarif, T.; Nassar, A.; Adib, E.; Fitzgerald, B.; Huang, J.; Mouhieddine, T.; Nonato, T.; McKay, R.; Li, M.; Mittra, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save